BioMarin Pharmaceutical Inc. Stock News

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The great advances and improvements in the treatment of diseases and the effectiveness of these medicines are undoubtedly due to technological progress and how biotech companies take advantage of it f

NEW YORK, Dec 20 (Reuters) - BioMarin (BMRN.O) reached a settlement with activist investor Elliott Investment Management where the biotechnology company will add three independent directors to its boa

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

In the fluctuating U.S. stock market, biotech stocks have faced challenges. The sector's most popular index, iShares Biotechnology ETF (NASDAQ: IBB ), is dropping 9% year to date (YTD).

Thanks to the biotechnology sector, the advances and improvement of processes within the health sector have been incredible. The impact with society and the contribution they make both directly and in

Among the large-cap stocks making big moves in today's market is drug maker BioMarin Pharmaceuticals (NASDAQ: BMRN ). Shares of BMRN stock surged more than 12% in early afternoon trading today on news

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Jean-Jacques Bienaime - Chairm

The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of BioMarin Pharmaceutical's once-daily injection to treat children under the age of 5 with the most common form of shor

During Q2 2023, BioMarin Pharmaceutical's revenues for the quarter has reached $595.3 million, a 12% YoY increase. The company's drug pipeline includes promising candidates for the treatment of rare d

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

SAN RAFAEL, Calif. , Oct. 17, 2023  /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will hos

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD

Label Expansion Decisions Expected from U.S. and European Regulatory Authorities in Q4 SAN RAFAEL, Calif. , Sept. 21, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotech

A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end.